---
trial_id: 313
discovery_date: 2022-04-02 17:30:16.022025
date: 2022-04-02 17:30:16.022025
title: "Multicenter, open-label, 12 weeks,
phaseIV pRospectivE randomized study aimed at evaLuating whether sc IFN beta 1a
(RebifÂ®) administered In the morning may affEct the severity of Flu-like syndrom..."
summary: |
  <p>EudraCT Number: 2013-004450-21<br />Sponsor Protocol Number: EMR200136-570<br />Sponsor Name: Merck Serono S.p.A.<br />Start Date: 2014-02-07<br />Medical condition: relapsing multiple sclerosis<br />Disease: <br />Version: 14.1<br />SOC Term: 10029205 - Nervous system disorders<br />Classification Code: 10028245<br />Term: Multiple sclerosis<br />Level: PT<br /><br />Population Age: Adults<br />Gender: Male, Female<br />Trial Protocol: <a href="https://www.clinicaltrialsregister.eu/ctr-search/trial/2013-004450-21/IT">IT</a> (Completed)</p>
link: 'https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2013-004450-21'
published_date: NaT
trial_source: Clinical Trials Register Europe
relevant: 
options:
  unlisted: false
---
<p>EudraCT Number: 2013-004450-21<br />Sponsor Protocol Number: EMR200136-570<br />Sponsor Name: Merck Serono S.p.A.<br />Start Date: 2014-02-07<br />Medical condition: relapsing multiple sclerosis<br />Disease: <br />Version: 14.1<br />SOC Term: 10029205 - Nervous system disorders<br />Classification Code: 10028245<br />Term: Multiple sclerosis<br />Level: PT<br /><br />Population Age: Adults<br />Gender: Male, Female<br />Trial Protocol: <a href="https://www.clinicaltrialsregister.eu/ctr-search/trial/2013-004450-21/IT">IT</a> (Completed)</p>